Co-Diagnostics Inc CODX.OQ CODX.O is expected to show a fall in quarterly revenue when it reports results on August 14 for the period ending June 30 2025
The Salt Lake City Utah-based company is expected to report a 94.4% decrease in revenue to $150 thousand from $2.66 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.
LSEG's mean analyst estimate for Co-Diagnostics Inc is for a loss of 62 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Co-Diagnostics Inc is $5.50, about 95.4% above its last closing price of $0.25
This summary was machine generated August 12 at 20:28 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)